• You are here: Home
  • B-lymphocyte Antigen CD20 Epitope Peptide Fragment, Bound To Rituximab (Fab Fragment). Indications For Rituximab Include Leukemia
B-lymphocyte antigen CD20 epitope peptide fragment, bound to rituximab (Fab fragment). Indications for rituximab include leukemia

  • Preview image in your
    Facebook Timeline Account

  • Preview

  • Price: 1$
  • Size Facebook: 1702 x 630 px
  • Size Twitter: 1500 x 500 px
  • Size LinkedIn: 1128 x 191 px

More Facebook, Twitter and LinkedIn Cover Photos

More

Cover photo info

  • Photo title: B-lymphocyte antigen CD20 epitope peptide fragment, bound to rituximab (Fab fragment). Indications for rituximab include leukemia
  • Author: Molekuul
  • Cover photo description:
  • B-lymphocyte antigen CD20 epitope peptide fragment, bound to rituximab (Fab fragment). Indications for rituximab include leukemia, lymphoma and rheumatoid arthritis. 3D rendering based on protein data bank entry 2osl. Stick representation combined with semi-transparent surfaces. Dark background
  • Image ID:188464569
  • Views:0
  • Downloads:2

Keywords for Facebook, Twitter and LinkedIn timeline photos

pdb2osl cd20 cd 20 cluster differentiation blymphocyte lymphocyte bcell antigen ms4a1 surface lymphoma leukemia immunohistochemistry histology antibody rituximab fab epitope autoimmune cancer rheumatoid arthritis purpura thrombocytopenic pemphigus vulgaris monoclonal structure peptide protein amino acid molecule polypeptide polymer atoms science scientific disease health molecular model 3d rendering illustration dark background black transparent artistic stylized

Similar images from Dreamstime

Humoral immunity. Lymphocyte, antibody and antigen Humoral immunity. antibody-mediated immunity. Viruse, Lymphocyte, antibody and antigen. Vector diagram for educational, biological B-lymphocyte antigen CD20 (theoretical model). Protein expressed on the surface of B-cells. Anti-CD20 monoclonal antibody drugs B-lymphocyte antigen CD20 (theoretical model). Protein expressed on the surface of B-cells. Anti-CD20 monoclonal antibody drugs B-lymphocyte antigen CD20 (theoretical model). Protein expressed on the surface of B-cells. Anti-CD20 monoclonal antibody drugs B-lymphocyte antigen CD20 epitope peptide fragment, bound to rituximab (Fab fragment). Indications for rituximab include leukemia
B-lymphocyte antigen CD20 (theoretical model). Protein expressed on the surface of B-cells. Anti-CD20 monoclonal antibody drugs B-lymphocyte antigen CD20 (theoretical model). Protein expressed on the surface of B-cells. Anti-CD20 monoclonal antibody drugs B-lymphocyte antigen CD20 epitope peptide fragment, bound to rituximab (Fab fragment). Indications for rituximab include leukemia B-lymphocyte antigen CD20 epitope peptide fragment, bound to rituximab (Fab fragment). Indications for rituximab include leukemia B-lymphocyte antigen CD20 epitope peptide fragment, bound to rituximab (Fab fragment). Indications for rituximab include leukemia
 
  • You are here: Home
  • B-lymphocyte Antigen CD20 Epitope Peptide Fragment, Bound To Rituximab (Fab Fragment). Indications For Rituximab Include Leukemia
x